IBC
13.5.2019 14:26:08 CEST | Business Wire | Press release
TM Forum, the industry association driving digital transformation through collaboration, and IBC, the world’s most influential media, entertainment and technology show, unveiled the details of three joint proof-of-concept Catalyst projects to be demonstrated at Digital Transformation World in Nice, France, May 14-16, 2019.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190513005442/en/
Catalysts are proof-of-concept projects developed collaboratively. These projects bring together companies large and small to create innovate solutions to common challenges demonstrating how this can be achieved leveraging key TM Forum best practices and standards.
These three unique Media-Telecom Convergence Catalyst projects are the first results of IBC and TM Forum’s collaboration aimed at driving open innovation between the telecoms and media industries. Featured among the 32 projects demonstrated at Digital Transformation World, they incorporate some of today’s most complex business and technology challenges today, including 5G, data management, virtual and augmented reality, edge computing, AI and the automation of business processes for regulatory compliance.
The three Media-Telecom Catalysts are:
-
5G-Enabled
Tourism Experience
This Catalyst explores ways of creating a pop-up network for delivery of high throughput broadcasting to distant points of fiber presence via mmWave connection. The project investigates how to deliver rich and engaging video-based experiences to users exploring an area of the Roman Baths in the UK and allows a mobile device to view a place as it would have been in the past. Champions: Aardman Entertainment, BBC R&D Participants: Bristol University, Cambridge Communications Systems Ltd., Zeetta Networks Ltd.
-
AI
Indexing for Regulatory Practice
This Catalyst is exploring ways to intelligently automate the identification of on-air content using AI in order to measure and report against compliance metrics set by external regulatory bodies, as well as for accurate measurement of internal editorial, creative and technical standards. Champions: Associated Press, Al Jazeera, RTE; Participants: Metaliquid, QCRI, Tech Mahindra, V-Nova
-
Mobile
News Gathering Using AI-Powered Compression
This Catalyst is working to empower newsrooms and journalists through improved intelligence for the mobile reporter in the field and faster time-to-air for both live and pre-recorded content. It leverages AI and techniques for improved bandwidth utilization through advanced compression techniques. Champions: Associated Press, Al Jazeera, RTE; Participant: V-Nova
“The convergence between telecom and media and entertainment has opened up exciting opportunities for our members to work alongside some of the world’s leading media companies to solve pressing business challenges,” said Andy Tiller, Executive Vice President, Collaboration and Innovation, TM Forum. “These three projects truly showcase how the power of collaboration helped find unique real-world solutions to problems faced by both industries – not only transforming businesses but consumer experience as well."
“As the pace of technology disruption and convergence accelerates, the rapid-fire Media-Telco Catalyst model for cross-sector innovation, partnerships and broader digital transformation is already proving a game-changing approach.” said Imran Sroya, Director, IBC. “We are delighted with the progress of the first three Catalyst projects and look forward to showcasing them at Digital Transformation World this month and at IBC in Amsterdam in September.”
Learn more about TM Forum’s Catalyst program at Digital Transformation World in Nice, France, May 14-16, 2019. With a focus on intelligent operations for a 5G world, Digital Transformation World showcases how businesses can seize opportunity and remain competitive in a rapidly evolving digital world. Click here for the latest event agenda: https://dtw.tmforum.org/agenda/
–Ends –
About TM Forum
TM Forum is an association of over 850-member companies’ customers across 180 countries. We drive collaboration and collective problem-solving to maximize the business success of communication and digital service providers and their ecosystem of suppliers around the world. Today, our focus is on supporting members as they navigate their unique digital transformation journeys, providing practical and proven assets and tools to accelerate execution and platforms to facilitate collaborative problem solving and innovation. Learn more at www.tmforum.org.
About IBC
IBC is the world’s most influential media, entertainment and technology show, attracting 55,000+ attendees from more than 170 countries and combining a highly respected and peer-reviewed conference with an exhibition that showcases 1,700+ leading industry suppliers of state-of-the-art technology. In addition to the world-class exhibition and conference, IBC also encompasses the IBC Daily, IBCTV and IBC365.
IBC365 provides year-round insight and opinion into the hot topics and key trends from leading industry journalists, along with insightful whitepapers, peer reviewed technical papers, highly engaging webinars and an expansive video library.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190513005442/en/
Contact:
CCgroup PR Anais Merlin E: TMForum@ccgrouppr.com T: +44 203 824 9200
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom